Why is F19Ap53 unable to bind MDM2? Simulations suggest crack propagation modulates binding

Cell Cycle

Volumn 11, Issue 12, 2012, Pages 2239-2247

  Dastidar, Shubhra Ghosh ^a   Lane, David P ^b   Verma, Chandra S ^c,d  

^a BOSE INSTITUTE   (India)

^b AGENCY FOR SCIENCE   (Singapore)

^c BIOINFORMATICS INSTITUTE   (Singapore)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Crack propagation; F19A; Kinetics; MDM2; p53; Thermodynamics

Indexed keywords

F19A PROTEIN; MEMBRANE PROTEIN; MUTANT PROTEIN; PROTEIN MDM2; PROTEIN P53; PROTEIN Y100; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; BINDING SITE; GENE INSERTION; MUTATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; THERMODYNAMICS; UBIQUITINATION; WILD TYPE;

PYRONIA TITHONUS;

EID: 84862899967     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20333     Document Type: Review

References (59)

1. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 2009; 9:862-73; PMID:19935675; http://dx.doi.org/10.1038/nrc2763.
2. Böttger A, Böttger V, Garcia-Echeverria C, Chène P, Hochkeppel HK, Sampson W, et al. Molecular characterization of the hdm2-p53 interaction. J Mol Biol 1997; 269:744-56; PMID:9223638; http://dx.doi.org/10. 1006/jmbi.1997.1078.
3. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, et al. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996; 274:948-53; PMID:8875929; http://dx.doi.org/10.1126/science.274.5289.948.
4. Zhong H, Carlson HA. Computational studies and peptidomimetic design for the human p53- MDM2 complex. Proteins 2005; 58:222-34; PMID:15505803; http://dx.doi.org/10.1002/prot.20275.
5. Zondlo SC, Lee AE, Zondlo NJ. Determinants of specificity of MDM2 for the activation domains of p53 and p65: proline27 disrupts the MDM2- binding motif of p53. Biochemistry 2006; 45:11945-57; PMID:17002294; http://dx.doi.org/10. 1021/bi060309g.
6. Böttger A, Böttger V, Sparks A, Liu WL, Howard SF, Lane DP. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo. Curr Biol 1997; 7:860-9; PMID:9382809; http://dx.doi.org/10.1016/S0960- 9822(06)00374-5.
7. Li C, Pazgier M, Li C, Yuan W, Liu M, Wei G, et al. Systematic mutational analysis of peptide inhibition of the p53-MDM2/MDMX interactions. J Mol Biol 2010; 398:200-13; PMID:20226197; http://dx.doi.org/10.1016/j.jmb.2010.03.005.
8. Lane DP, Cheok CF, Lain S. p53-based cancer therapy. Cold Spring Harb Perspect Biol 2010; 2:a001222; PMID:20463003; http://dx.doi.org/10.1101/ cshperspect.a001222.
9. Chen J. Intrinsically disordered p53 extreme C-terminus binds to S100B(betabeta) through "fly-casting". J Am Chem Soc 2009; 131:2088- 9; PMID:19216110; http://dx.doi.org/10.1021/ja809547p.
10. Gsponer J, Babu MM. The rules of disorder or why disorder rules. Prog Biophys Mol Biol 2009; 99:94- 103; PMID:19344736; http://dx.doi.org/10.1016/j. pbiomolbio.2009.03.001.
11. Huang Y, Liu Z. Kinetic advantage of intrinsically disordered proteins in coupled folding-binding process: a critical assessment of the "fly-casting" mechanism. J Mol Biol 2009; 393:1143-59; PMID:19747922;http://dx.doi.org/10.1016/j.jmb.2009.09.010.
12. Dastidar SG, Lane DP, Verma CS. Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100. BMC Bioinformatics 2009; 10:6; PMID:19126227; http://dx.doi.org/10.1186/1471-2105-10-S15-S6.
13. Dastidar SG. others a. Forces mediating proteinprotein interactions: a computational study of p53 "approaching" MDM2. Theor Chem Acc 2010; 125:621; http://dx.doi.org/10.1007/s00214-009-0682-1.
14. Dunker AK, Uversky VN. Signal transduction via unstructured protein conduits. Nat Chem Biol 2008; 4:229-30; PMID:18347590; http://dx.doi.org/10. 1038/nchembio0408-229.
15. Wang Y, Fisher JC, Mathew R, Ou L, Otieno S, Sublet J, et al. Intrinsic disorder mediates the diverse regulatory functions of the Cdk inhibitor p21. Nat Chem Biol 2011; 7:214-21; PMID:21358637; http://dx.doi.org/10.1038/nchembio. 536.
16. Chen HF. Molecular dynamics simulation of phosphorylated KID post-translational modification. PLoS One 2009; 4:e6516; PMID:19654879; http://dx.doi.org/10.1371/journal.pone.0006516.
17. Cortese MS, Uversky VN, Dunker AK. Intrinsic disorder in scaffold proteins: getting more from less. Prog Biophys Mol Biol 2008; 98:85-106; PMID:18619997; http://dx.doi.org/10.1016/j.pbiomolbio.2008.05.007.
18. Lacy ER, Filippov I, Lewis WS, Otieno S, Xiao L, Weiss S, et al. p27 binds cyclin-CDK complexes through a sequential mechanism involving binding- induced protein folding. Nat Struct Mol Biol 2004; 11:358-64; PMID:15024385; http://dx.doi. org/10.1038/nsmb746.
19. Shoemaker BA, Portman JJ, Wolynes PG. Speeding molecular recognition by using the folding funnel: the fly-casting mechanism. Proc Natl Acad Sci U S A 2000; 97:8868-73; PMID:10908673; http://dx.doi.org/10.1073/pnas.160259697.
20. Sugase K, Dyson HJ, Wright PE. Mechanism of coupled folding and binding of an intrinsically disordered protein. Nature 2007; 447:1021-5; PMID:17522630; http://dx.doi.org/10.1038/nature05858.
21. Trizac E, Levy Y, Wolynes PG. Capillarity theory for the fly-casting mechanism. Proc Natl Acad Sci U S A 2010; 107:2746-50; PMID:20133683; http://dx.doi.org/10.1073/pnas.0914727107.
22. Verkhivker GM, Bouzida D, Gehlhaar DK, Rejto PA, Freer ST, Rose PW. Simulating disorder-order transitions in molecular recognition of unstructured proteins: where folding meets binding. Proc Natl Acad Sci U S A 2003; 100:5148-53; PMID:12697905; http://dx.doi.org/10.1073/pnas.0531373100.
23. Uhrinova S, Uhrin D, Powers H, Watt K, Zheleva D, Fischer P, et al. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol 2005; 350:587- 98; PMID:15953616; http://dx.doi.org/10.1016/j.jmb.2005.05.010.
24. Buch I, Giorgino T, De Fabritiis G. Complete reconstruction of an enzyme-inhibitor binding process by molecular dynamics simulations. Proc Natl Acad Sci U S A 2011; 108:10184-9; PMID:21646537; http://dx.doi.org/10.1073/pnas. 1103547108.
25. Dror RO, Arlow DH, Borhani DW, Jensen MO, Piana S, Shaw DE. Identification of two distinct inactive conformations of the beta2-adrenergic receptor reconciles structural and biochemical observations. Proc Natl Acad Sci U S A 2009; 106:4689-94; PMID:19258456; http://dx.doi.org/10.1073/pnas. 0811065106.
26. Shaw DE, Maragakis P, Lindorff-Larsen K, Piana S, Dror RO, Eastwood MP, et al. Atomic-level characterization of the structural dynamics of proteins. Science 2010; 330:341-6; PMID:20947758; http://dx.doi.org/10.1126/science. 1187409.
27. Dastidar SG, Lane DP, Verma CS. Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. J Am Chem Soc 2008; 130:13514-5; http://dx.doi.org/10.1021/ja804289g; PMID:18800837.
28. Liu Z, Olejniczak ET, Fesik SW. Over-expression of the human MDM2 p53 binding domain by fusion to a p53 transactivation peptide. Protein Expr Purif 2004; 37:493-8; PMID:15358376; http://dx.doi.org/10.1016/j.pep.2004.06.036.
29. Schon O, Friedler A, Bycroft M, Freund SM, Fersht AR. Molecular mechanism of the interaction between MDM2 and p53. J Mol Biol 2002; 323:491-501; PMID:12381304; http://dx.doi.org/10.1016/S0022-2836(02)00852-5.
30. Medina M, Abagyan R, Gómez-Moreno C, Fernandez-Recio J. Docking analysis of transient complexes: interaction of ferredoxin-NADP+ reductase with ferredoxin and flavodoxin. Proteins 2008; 72:848-62; PMID:18260112; http://dx.doi.org/10.1002/prot.21979.
31. Waas WF, Dalby KN. Transient protein-protein interactions and a random-ordered kinetic mechanism for the phosphorylation of a transcription factor by extracellular-regulated protein kinase 2. J Biol Chem 2002; 277:12532-40; PMID:11812784;http://dx.doi.org/10.1074/jbc.M110523200.
32. Buolamwini JK, Addo J, Kamath S, Patil S, Mason D, Ores M. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents. Curr Cancer Drug Targets 2005; 5:57-68; PMID:15720190; http://dx.doi.org/10.2174/ 1568009053332672.
33. Khoury K, Popowicz GM, Holak TA, Dömling A. The p53-MDM2/MDMX axis - A chemotype perspective. Med Chem Commun 2011; 2:246-60; http://dx.doi.org/10. 1039/c0md00248h.
34. Nicholson J, Hupp TR. The molecular dynamics of MDM2. Cell Cycle 2010; 9:1878-81; PMID:20436290; http://dx.doi.org/10.4161/cc.9.10.11597.
35. Joseph TL, Madhumalar A, Brown CJ, Lane DP, Verma CS. Differential binding of p53 and nutlin to MDM2 and MDMX: computational studies. Cell Cycle 2010; 9:1167-81; PMID:20190571; http://dx.doi.org/10.4161/cc.9.6.11067.
36. Wallace M, Worrall E, Pettersson S, Hupp TR, Ball KL. Dual-site regulation of MDM2 E3-ubiquitin ligase activity. Mol Cell 2006; 23:251-63; PMID:16857591; http://dx.doi.org/10.1016/j.molcel.2006.05.029.
37. Coutts AS, Adams CJ, La Thangue NB. p53 ubiquitination by Mdm2: a never ending tail? DNA Repair (Amst) 2009; 8:483-90; PMID:19217357; http://dx.doi.org/10.1016/j.dnarep.2009.01.008.
38. Popowicz GM, Czarna A, Rothweiler U, Szwagierczak A, Krajewski M, Weber L, et al. Molecular basis for the inhibition of p53 by Mdmx. Cell Cycle 2007; 6:2386-92; PMID:17938582; http://dx.doi.org/10.4161/cc.6.19.4740.
39. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303:844-8; PMID:14704432; http://dx.doi.org/10.1126/science. 1092472.
40. Fry DC, Emerson SD, Palme S, Vu BT, Liu CM, Podlaski F. NMR structure of a complex between MDM2 and a small molecule inhibitor. J Biomol NMR 2004; 30:163-73; PMID:15557803; http://dx.doi.org/10.1023/B:JNMR.0000048856.84603.9b.
41. Liu Y, Lane DP, Verma CS. Systematic mutational analysis of an ubiquitin ligase (MDM2)-binding peptide: computational studies. Theor Chem Acc 2011;130:1145-54; http://dx.doi.org/10.1007/s00214-011-1049-y.
42. Kashuba E, Yurchenko M, Yenamandra SP, Snopok B, Szekely L, Bercovich B, et al. Epstein-Barr virusencoded EBNA-5 forms trimolecular protein complexes with MDM2 and p53 and inhibits the transactivating function of p53. Int J Cancer 2011; 128:817-25; PMID:20473904; http://dx.doi.org/10.1002/ijc.25414.
43. Lane DP, Brown CJ, Verma C, Cheok CF. New insights into p53 based therapy. Discov Med 2011; 12:107-17; PMID:21878188.
44. Frauenfelder H, Sligar SG, Wolynes PG. The energy landscapes and motions of proteins. Science 1991; 254:1598-603; PMID:1749933; http://dx.doi.org/10. 1126/science.1749933.
45. García AE. Large-amplitude nonlinear motions in proteins. Phys Rev Lett 1992; 68:2696-9; PMID:10045464; http://dx.doi.org/10.1103/PhysRevLett.68. 2696.
46. Kitao A, Hayward S, Go N. Energy landscape of a native protein: jumping-amongminima model. Proteins 1998; 33:496-517; PMID:9849935; http://dx.doi.org/10.1002/ (SICI) 1097-0134(19981201)33:4<496 : :AIDPROT4>3.0.CO;2-1.
47. Miyashita O, Onuchic JN, Wolynes PG. Nonlinear elasticity, proteinquakes, and the energy landscapes of functional transitions in proteins. Proc Natl Acad Sci U S A 2003; 100:12570-5; PMID:14566052; http://dx.doi.org/10.1073/pnas. 2135471100.
48. Xie A, Kelemen L, Hendriks J, White BJ, Hellingwerf KJ, Hoff WD. Formation of a new buried charge drives a large-amplitude protein quake in photoreceptor activation. Biochemistry 2001; 40:1510-7; PMID:11327809; http://dx.doi.org/10.1021/bi002449a.
49. Marszalek PE, Lu H, Li H, Carrion-Vazquez M, Oberhauser AF, Schulten K, et al. Mechanical unfolding intermediates in titin modules. Nature 1999; 402:100-3; PMID:10573426; http://dx.doi.org/10.1038/47083.
50. Buehler MJ. Mechanics of Protein Crystals: Atomistic Modeling of Elasticity and Fracture. J Theor and comput. Nanotechnology 2006; 3:670-83. (Pubitemid 44972942)
51. Hyeon C, Onuchic JN. Mechanical control of the directional stepping dynamics of the kinesin motor. Proc Natl Acad Sci U S A 2007; 104:17382-7; PMID:17959770; http://dx.doi.org/10.1073/pnas.0708828104.
52. Whitford PC, Onuchic JN, Wolynes PG. Energy landscape along an enzymatic reaction trajectory: hinges or cracks? HFSP J 2008; 2:61-4; PMID:19404472; http://dx.doi.org/10.2976/1.2894846.
53. de Graff AM, Shannon G, Farrell DW, Williams PM, Thorpe MF. Protein unfolding under force: crack propagation in a network. Biophys J 2011; 101:736- 44; PMID:21806942; http://dx.doi.org/10.1016/j.bpj.2011.05.072.
54. Shan Y, Kim ET, Eastwood MP, Dror RO, Seeliger MA, Shaw DE. How does a drug molecule find its target binding site? J Am Chem Soc 2011; 133:9181- 3; PMID:21545110; http://dx.doi.org/10.1021/ja202726y.
55. Galea CA, Nourse A, Wang Y, Sivakolundu SG, Heller WT, Kriwacki RW. Role of intrinsic flexibility in signal transduction mediated by the cell cycle regulator, p27 Kip1. J Mol Biol 2008; 376:827-38; PMID:18177895; http://dx.doi.org/10.1016/j.jmb.2007.12.016.
56. Kinetic recognition of the retinoblastoma tumor suppressor by a specific protein target. Chemes LBSánchez IEde Prat-Gay GJ. Mol Biol 2011; 412:267-84; http://dx.doi.org/10.1016/j.jmb.2011.07.015.
57. Isin EM, Guengerich FP. Multiple sequential steps involved in the binding of inhibitors to cytochrome P450 3A4. J Biol Chem 2007; 282:6863- 74; PMID:17200113; http://dx.doi.org/10.1074/jbc.M610346200.
58. Joseph TL, Lane D, Verma CS. Stapled peptides in the p53 pathway: computer simulations reveal novel interactions of the staples with the target protein. Cell Cycle 2010; 9:4560-8; PMID:21088491; http://dx.doi.org/10.4161/cc. 9.22.13816.
59. Kim YW, Grossmann TN, Verdine GL. Synthesis of all-hydrocarbon stapled a-helical peptides by ringclosing olefin metathesis. Nat Protoc 2011; 6:761- 71; PMID:21637196; http://dx.doi.org/10.1038/nprot.2011.324.